Coherus Oncology (CHRS) Current Deferred Revenue (2013 - 2017)
Coherus Oncology (CHRS) posted Current Deferred Revenue of $669000.0 for Q1 2017, down 25.0% sequentially from $892000.0 in Q4 2016, and down 98.65% YoY from $49.6 million in Q1 2016.
Coherus Oncology (CHRS) Current Deferred Revenue (2013 - 2017) Analysis & Trends
Coherus Oncology has reported Current Deferred Revenue for 5 years, with the latest figure at $669000.0 in Q1 2017.
- Quarterly Current Deferred Revenue fell 98.65% year-over-year to $669000.0 in Q1 2017, while the trailing twelve-month figure through Mar 2017 was $669000.0 (down 98.65% YoY) and the FY2016 annual result came in at $892000.0, down 98.2% from the prior year.
- Current Deferred Revenue retreated to $669000.0 in Q1 2017 per CHRS's latest filing, from $892000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $61.3 million in Q2 2016 and troughed at $162000.0 in Q1 2015.
- A 5-year average of $22.0 million and a median of $22.8 million in 2014 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2016 and 2017: Current Deferred Revenue jumped 30537.65% in 2016, then plunged 98.65% in 2017.
- Over 5 years, Current Deferred Revenue stood at $14.3 million in 2013, then soared by 59.63% to $22.8 million in 2014, then surged by 117.64% to $49.6 million in 2015, then tumbled by 98.2% to $892000.0 in 2016, then retreated by 25.0% to $669000.0 in 2017.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $669000.0, $892000.0, and $1.4 million for Q1 2017, Q4 2016, and Q3 2016 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 669,000.00 |
| Dec 31, 2016 | 892,000.00 |
| Sep 30, 2016 | 1.38 Mn |
| Jun 30, 2016 | 61.26 Mn |
| Mar 31, 2016 | 49.63 Mn |
| Dec 31, 2015 | 49.62 Mn |
| Sep 30, 2015 | 28.85 Mn |
| Jun 30, 2015 | 31.01 Mn |
| Mar 31, 2015 | 162,000.00 |
| Dec 31, 2014 | 22.80 Mn |
| Sep 30, 2014 | 25.18 Mn |
| Mar 31, 2014 | 300,000.00 |
| Dec 31, 2013 | 14.28 Mn |